Liver and Kidney Transplant During a 6-Month Period in the COVID-19 Pandemic: A Single-Center Experience

• Published in: Experimental and clinical transplantation Vol. 18; no. 5; pp. 564 - 571
• Main Authors: Akdur, Aydincan, Karakaya, Emre, Ayvazoglu Soy, Ebru H, Yarbug Karakayali, Feza, Yildirim, Sedat, Torgay, Adnan, Sayin, Cihat Burak, Coskun, Mehmet, Moray, Gokhan, Haberal, Mehmet
• Format: Journal Article
• Language: English
• Published: Turkey Başkent Üniversitesi 01.10.2020
• Subjects: Adolescent; Adult; Child; Child, Preschool; Coronavirus Infections; COVID-19; Delivery of Health Care - trends; Female; Humans; Immunocompromised Host; Immunosuppressive Agents - administration & dosage; Kidney Transplantation - adverse effects; Kidney Transplantation - trends; Liver Transplantation - adverse effects; Liver Transplantation - trends; Male; Middle Aged; Outcome and Process Assessment, Health Care - trends; Pandemics; Patient Safety; Pneumonia, Viral; Risk Assessment; Risk Factors; Time Factors; Tıp; Treatment Outcome; Turkey; Waiting Lists; Young Adult; Turkey; Ankara; Türkiye; Donor selection; Transplant recipients; Organ transplants
• ISSN: 1304-0855; 2146-8427
• DOI: 10.6002/ect.2020.0388

With the declaration of COVID-19 as a pandemic, many studies have indicated that elective surgeries should be postponed. However, postponement of transplants may cause diseases to get worse and increase the number in wait lists. We believe that, with precautions, transplant does not pose a risk during pandemic. Here, we aimed to evaluate our transplant results, which we safely performed during a 6-month pandemic period. Until September 2020, 3140 kidney and 667 liver transplants have been performed in our centers. We evaluated 38 kidney transplants and 9 liver transplants procedures performed during the pandemic (March 1 to September 2, 2020). Recipient and donor candidates were screened for COVID-19 with polymerase chain reaction and thoracic computed tomography. All recipients had routine immunosuppressive protocol. During hospitalization at our COVID-19-free transplant facility, we restricted the interactions during multidisciplinary rounds. During the pandemic, 38 kidney transplants with an average length of hospital stay of 8.1 days were performed. Mean serum creatinine values of recipients were 0.91, 0.86, and 0.74 mg/dL on postoperative days 7, 30, and 90, respectively. During the pandemic, 9 living donor liver transplants (1 adult, 8 pediatric) were performed with an average length of hospital stay of 17.1 days. Mean serum total bilirubin levels were 0.9, 0.5, and 0.4 mg/dL on postoperative days 7, 30, and 90, respectively. Mean serum aspartate aminotransferase levels were 38.1, 28.3, and 22.3 U/L on postoperative days 7, 30, and 90, respectively. All recipients and donors were successfully discharged. Only 1 liver recipient died (on day 55 after discharge as a result of oxalosis-induced heart failure). According to our results, when precautions are taken, transplant does not pose a risk to patients during the pandemic period. We attribute the safety and success shown to our newly developed protocol in response to the COVID-19 pandemic.